Triple-negative breast cancer trials in Netherlands

In Netherlands 13 Also abroad 425

13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Where
Amersfoort, Arnhem, Deventer, Groningen, Rotterdam, Sittard Geleen, Tilburg
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00
Phase 3Taking people
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Where
Amsterdam, Hoofddorp, Maastricht, Rotterdam, 's-Gravenhage
Age
18 years and over
People
558 worldwide
Run by
BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00
Phase 2Taking people
Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
Where
Amsterdam
Age
18 years and over
People
153
Run by
Netherlands Cancer Institute
See details and how to joinNCT06279130 · EU 2023-505756-21-00
No phaseTaking people
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Where
Amsterdam, Breda, Deventer, Enschede, Groningen, Maastricht, Nijmegen, Rotterdam
Age
18 years and over
People
100
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06931769
Phase 1/2Taking people
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Where
Amsterdam, Leiden
Age
18 years and over
People
416 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT06618287
Phase 1Taking people
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Where
Nijmegen, Utrecht
Age
18 years to 100 years
People
162 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06562192
Phase 1Taking people
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Where
Amsterdam
Age
18 years and over
People
714 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00
No phaseTaking people
The TASTY-steering Study
Where
Amsterdam, Arnhem, Dirksland, Ede, Groningen, Nijmegen, Rotterdam, Scheemda, Veldhoven, Zwolle
Age
18 years to 70 years
People
201
Run by
University Medical Center Groningen
See details and how to joinNCT07258563
Phase 3Not yet taking people in Netherlands
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus Chemotherapy
Where
Alkmaar, Almelo, Almere, Amersfoort, Amstelveen, Amsterdam, Apeldoorn, Arnhem, Assen, Beverwijk, Breda, Capelle aan den IJssel, Delft, Deventer, Dirksland, Doetinchem, Dordrecht, Drachten, Ede Gld, Eindhoven, Emmen, Enschede, Geldrop, Goes, Gorinchem, Gouda, Groningen, Harderwijk, Heerlen, Hilversum, Hoofddorp, Hoorn Nh, Leeuwarden, Leiderdorp, Leidschendam, Maastricht, Nieuwegein, Nijmegen, Roermond, Roosendaal, Rotterdam, Scheemda, Schiedam, 's-Gravenhage, 'S-Hertogenbosch, Sneek, Terneuzen, Tilburg, Uden, Utrecht, Venlo, Weert, Winterswijk, Zaandam, Zwolle
Age
18 years and over
People
1,000
Run by
The Netherlands Cancer Institute
See details and how to joinNCT07486687 · EU 2025-524229-41-00
Phase 1/2Taking people
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Where
Maastricht, Rotterdam
Age
18 years and over
People
126 worldwide
Run by
Maastricht University Medical Center
See details and how to joinNCT04954599
No phaseTaking people
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
Where
Alkmaar, Almere Stad, Amersfoort, Amsterdam, Arnhem, Breda, Deventer, Ede, Eindhoven, Enschede, Harderwijk, Hengelo, Hilversum, Hoofddorp, Hoorn, Leeuwarden, Leiden, Maastricht, Nieuwegein, Nijmegen, Rotterdam, Schiedam, Sittard-Geleen, The Hague, Venlo, Zwolle
Age
18 years and over
People
490
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06476119
Phase 2Taking people
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
Where
Amsterdam
Age
18 years and over
People
60
Run by
The Netherlands Cancer Institute
See details and how to joinNCT06342037
Phase 2Taking people
Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients
Where
Amsterdam
Age
18 years and over
People
52
Run by
The Netherlands Cancer Institute
See details and how to joinNCT04159818 · EU 2024-513217-12-00